The US Food and Drug Administration’s recent warning letters to drug manufacturers and active pharmaceutical ingredient manufacturers in the US and India show that data integrity problems are not going away anytime soon, despite the inspection hiatus that was brought on by the coronavirus pandemic.
Also, the International Council on Harmonization proposes to add three new residual solvents to the list of solvents considered safe in pharmaceuticals in a Step 2 guidance.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?